Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 29 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... April 15, 2025 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... January 5, 2021 Boy Asks Mom Fighting Cancer To Take Off Her Turban So... May 4, 2020 Load more HOT NEWS An Updated Overview of Estimates for Cancer Incidence and Mortality in... Change Your Thoughts, Change Your World Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback
